MYX 2.23% $4.38 mayne pharma group limited

Ann: 2023 Full Year Results Investor Presentation, page-34

  1. 911 Posts.
    lightbulb Created with Sketch. 53
    There is actually 70 m savings in operating expenses , so Mayne is operating both Nexstellis and TXMD at profit for the first time , so they are correct 14 m +ve contribution and international segment always making profit , hopefully they add more dermatology products from similar companies to use the existing sales force . Smart idea
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.